SUMMARY

• Janssen does not recommend the use of TALVEY in a manner that is inconsistent with the approved labeling.
• MonumenTAL-1 is an ongoing, open-label, phase 1/2 study evaluating the efficacy and safety of TALVEY in patients with relapsed or refractory multiple myeloma (RRMM) after ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI), an immunomodulatory drug, and an anti-CD38 monoclonal antibody (mAb).^1-3
  • Per protocol, patients with central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma (MM), were excluded from enrollment.⁴
• A search of the scientific literature retrieved limited information from 2 congress posters, describing the use of TALVEY in the included patients with MM and CNS involvement:
  • Mersi J, Eisele F, Zhou X, et al. The role of bispecific antibodies and CAR T cells in the treatment of multiple myeloma with central nervous system involvement. Poster presented at: European Hematology Association (EHA) 2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.
  • Gill SK, Fleming E, Gebre H, et al. Real world outcomes with talquetamab, a T-cell-redirecting GPRC5D bispecific antibody: A single center experience for relapsed/ refractory multiple myeloma (RRMM). Presented at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition; December 7-10, 2024; San Diego, California. 

literature search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 02 June 2025.